Plasma concentration of selected neoplastic markers in persons occupationally exposed to arsenic and heavy metals;Analiza stȩżeń wybranych markerów neoplazmatycznych u osób zawodowo narażonych na arsen i metale ciȩżkie

Medycyna Pracy

Volumn 55, Issue 4, 2004, Pages 313-320

  Szymańska Chabowska, Anna ^a,b   Antonowicz Juchniewicz, Jolanta ^a   Andrzejak, Ryszard ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b NONE   (Poland)

Author keywords

Arsenic; Cadmium neoplastic markers; Carcinogenesis; Lead

Indexed keywords

ARSENIC; CADMIUM; CARCINOGEN; COPPER; ERYTHROCYTE PROTOPORPHYRIN; HEAVY METAL; LEAD; TUMOR MARKER; CARCINOEMBRYONIC ANTIGEN; ONCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTOPORPHYRIN; SERINE PROTEINASE INHIBITOR; SQUAMOUS CELL CARCINOMA RELATED ANTIGEN; SQUAMOUS CELL CARCINOMA-RELATED ANTIGEN; TUMOR ANTIGEN; ZINC;

ARSENIC POISONING; BLOOD LEVEL; CADMIUM POISONING; CANCER RISK; CARCINOGENIC ACTIVITY; CIGARETTE SMOKING; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; CORRELATION ANALYSIS; HUMAN; LEAD BLOOD LEVEL; LEAD POISONING; NEOPLASM; OCCUPATIONAL EXPOSURE; SMELTER; ADULT; AIR POLLUTANT; ARTICLE; BLOOD; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; MALE; METHODOLOGY; MIDDLE AGED; OCCUPATIONAL DISEASE; POLAND; RISK FACTOR; URINE;

ADULT; AIR POLLUTANTS, OCCUPATIONAL; ANTIGENS, NEOPLASM; ARSENIC; CADMIUM; CARCINOEMBRYONIC ANTIGEN; COPPER; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; HUMANS; LEAD; MALE; METALS, HEAVY; MIDDLE AGED; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; ONCOGENE PROTEINS; POLAND; PROSTATE-SPECIFIC ANTIGEN; PROTOPORPHYRINS; RISK FACTORS; SERPINS; TUMOR MARKERS, BIOLOGICAL; ZINC;

EID: 4544302659     PISSN: 04655893     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (60)

1. Analyses of Hazardous Substances in Biological Materials. Angerer J., Schaller K.H. [red.]. Working Group Analytical Chemistry. T. 3. John Wiley & Sons Limited 1991.
2. Apostoli P., Alessio L.: Metabolism of arsenic after acute occupational arsine intoxication. J. Toxicol. Environ. Health 1997; 52: 331-342.
3. Axelson O., Dahlgren E., Jansson C.D., Rehnlund S.O.: Arsenic exposure and mortality: a case referent study from a Swedish copper smelter. Br. J. Ind. Med. 1978; 35: 8-15.
4. Beckman L., Nordenson I.: Interaction between some common genotoxic agents. Hum. Hered. 1986; 36: 397-401.
5. Chen C.J., Wang C.J.: Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res. 1990; 50: 5470-5474.
6. Jakubowski M.: Arsen i jego zwia̧zki nieorganiczne (w przeliczeniu na As). Zespół Ekspertów ds. Czynników Chemicznych Miȩdzyresortowej Komisji ds. Aktualizacji Wykazu NDS i NDN, Łódź 1996, ss. 1-20.
7. Enterline P.E., Marsh G.M., Esmen N.A., Henderson V.L., Callahan C.M., Paik M. i wsp.: Some effects of cigarette smoking, arsenic, and SO2 on mortality among US copper smelter workers. J. Occup. Med. 1987; 29 (10): 831-838.
8. Magos L.: Epidemiological and experimental aspects of metal carcinogenesis: physiochemical properties, kinetics and the active species. Environ. Health Perspect. 1991; 95: 157-189.
9. Kenyon E.M., Hughes M.F.: A concise review of the toxicity and carcinogenicity of dimethylarsinic acid. Toxicology 2001; 160 (1-3): 227-236.
10. Leonard A., Lauwerys R.R.: Carcinogenicity, teratogenicity and mutagenicity of arsenic. Mut. Res. 1980; 75: 49-62.
11. Rossman T. G.: Metal mutagenesis. Hand Exp. Pharm. 1995; 115: 373-409.
12. Boffetta P.: Carcinogenicity of trace elements with reference to evaluations made by the IARC. Scand. J. Work. Environ. Health 1993; 19 Supl. 1: 67-70.
13. Hsu Y.H., Li S.Y., Chiou H.Y., Yeh P.M., Liou J.C., Hsueh Y.M. i wsp.: Spontaneous and induced sister chromatid exchanges and delayed cell proliferation in peripheral lymphocytes of Bowen's disease patients and matched controls of arseniasis-hyperendemic villages in Taiwan. Mut. Res. 1997; 386: 241-251.
14. Lerda D.: Sister-chromatid exchange (SCE) among individuals chronically exposed to arsenic in drinking water. Mut. Res. 1994; 312: 111-120.
15. Bettley F.R., O'Shea J.A.: The absorption of arsenic and its relation to carcinoma. Br. J. Dermatol. 1975; 92: 563-569.
16. Biggs M.L., Kalman D.A., Moore L.E., Hopenhayn-Rich C., Smith M.T., Smith A.H.: Relationship of urinary arsenic to intake estimates and a biomarker of effect, bladder cell micronuclei. Mut. Res. 1997; 386: 185-195.
17. Cantor K.P.: Invited commentary: arsenic and cancer of the urinary tract. Am. J. Epidemiol. 2001; 153 (5): 419-423.
18. Chen C.J., Chen C.W., Wu M.M., Kuo T.L.: Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br. J. Cancer 1992; 66: 888-892.
19. Chiou A.Y., Hsueh Y.M., Liaw K.F., Horng S.F., Chiang M.H., Pu Y.S. i wsp.: Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res. 1995; 55 (6): 1296-1300.
20. Germolec D.R., Spalding J., Boorman G.A., Wilmer J.L., Yoshida T., Simeonova P.P. i wsp.: Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors. Mutat. Res. 1997; 386 (3): 209-218.
21. Jager J.W., Ostrosky-Wegman P.: Arsenic: a paradoxical human carcinogen. Mut. Res. 1997; 386: 181-184.
22. Mass M.J., Wang L.: Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mut. Res. 1997; 386: 263-277.
23. Zhao C.Q., Young M.R., Diwan B.A., Coogan T.P., Waalkes M.P. Association of arsenic - induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc. Natl. Acad. Sci. USA. 1997; 94 (20): 10907-10912.
24. Luster M.I., Wilmer J.L., Germolec D.R., Spalding J., Yoshida T., Gaido K. i wsp.: Role of keratinocyte-derived cytokines in chemical toxicity. Toxicol. Lett. 1995; 82/83: 471-476.
25. Bernstam L., Nriagu J.: Molecular aspects of arsenic stress. J. Toxicol. Environ. Health B. Crit. Rev. 20003; (4): 293-322.
26. Bradley D.: Therapeutic needs revive arsenic compound. Pharm. Sci Technol. Today 2000; 3 (12): 401.
27. Dong Z.: Molecular mechanism of carcinogenic and anti-cancer effects by arsenic. Metal Ions Biol. Med. 2000; 6: 44-46.
28. Liu S.X., Athar M., Lippai I., Waldren C., Hei T.K.: Induction of oxyradicals by arsenic: implication for mechanism of genotoxicity. Proc. Natl. Acad. Sci USA 2001; 98 (4): 1643-1648.
29. Santra A., Maiti A., Chowdhury A., Mazumder D.R.: Oxidative stress in liver of mice exposed to arsenic-contaminated water. Indian. J. Gastroenterol. 2000; 19(3): 112-115.
30. Barchowsky A., Klei L.R., Dudek E.J., Swartz H.M., James P.E.: Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radic. Biol. Med. 1999; 27 (11-12): 1405-1412.
31. Barchowsky A., Klei L.R., Smith K.R., Ross Ch.R.: Oxidant signaling mechanisms initiated by low levels of arsenic in vascular cells. Metal Ions Biol. Med. 2000; 6: 47-49.
32. Dong J.T., Luo X.M.: Arsenic-induced DNA-strand breaks associated with DNA-protein crosslinks in human fetal lung fibroblasts. Mut. Res. 1993; 302: 97-102.
33. Gebel T.W.: Genotoxicity of arsenical compounds. Int. J. Hyg. Environ. Health 2001; 203 (3): 249-262.
34. Harris C.C.: Interindividual variation among humans in carcinogen metabolism, DNA adduct formation and DNA repair. Carcinogenesis 1998; 10: 1563-1566.
35. Hussain S.P., Harris C.C.: Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res. 1998; 58: 4023-4037.
36. Simeonova P.P., Luster M.I.: Mechanism of arsenic carcinogenicity: genetic or epigenetic mechanisms? J. Environ. Pathol. Toxicol. Oncol. 2000; 19 (3): 281-286.
37. Li J.H., Rossman T.G.: Inhibition of DNA ligase activity by arsenic: a possible mechanism of its comutagenesis. Mol. Toxicol. 1989; 2: 1-9.
38. Raport Komisji Toksykologicznej Rady Sanitarno-Epidemiologicznej: Ogólna ocena toksykologicznego zagrożenia kadmem w Polsce. Med. Pr. 1995; 5 Supl. 5: 7-23.
39. Barret J.C., Shelby M.D.: Mechanisms of multistep carcinogenesis: keys to developing in vitro approaches for assessing the carcinogenicity of chemicals. Food Chem. Toxicol. 1986; 24 (6/7): 657-661.
40. Gerhardsson L., Nordberg G.F.: Lung cancer in smelter workers - interactions of metals as indicated by tissue levels. Scand. J. Work. Environ. Health 1993; 19 Supl. 1: 90-94.
41. ASCO (American Society of Clinical Oncology): Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J. Clin. Oncol. 1996;14 (10): 2843-2877.
42. Bar J.K., Harłozińska A.: Clinical utility of p53 and c-erbB-2 immunostaining in the diagnosis of tumor effusions. Diagn. Oncol. 1994-1995; 4: 224-229.
43. Chapman M.A.S., Buckley D., Henson D.B., Armitage N.C.: Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer. Br. J. Cancer 1998; 78 (10): 1346-1349.
44. Gisterek I.: Clinically useful tumor markers. International Intensive Course of Oncology, Erasmus 1999; 99: 211-221.
45. Hammarstrom S.: The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin. Cancer Biol. 1999; 9 (2): 67-81.
46. Szymendera J.J., Góźdź S.S.: Rola kra̧ża̧cych markerów nowotworowych w diagnostyce i monitorowaniu leczenia chorych na nowotwory. Nowotwory 1995; 45: 369-383.
47. Harłozińska- Szmyrka A.: Nowotwory jako choroba genów. Postepy Biochem. 1995; 41 (1): 7-15.
48. Hurwitz M., Sawicki M., Samara G., Passaro E.: Diagnostic and prognostic molecular markers in cancer. Am. J. Surg. 1992; 164: 299-306.
49. Kulpa J., Wójcik E. Radkowski A., Kołodziejski L., Stasik Z.: CYFRA 21-1, TPA-M, TPS,, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group. Anticancer Res. 2000; 20: 5035-5040.
50. Senn H.J., Drings P., Glaus A., Jungi W.S., Sauer R., Schlak P.: Biochemical tumor markers. Kompendium Onkologii. Państwowy Zakład Wydawnictw Lekarskich, Warszawa 1995.
51. Nikliński J., Furman M., Moniuszko-Jakoniuk J., Laudański J.: Antygen SCC-Ag w surowicy chorych na pierwotnego niedrobnokomórkowego raka płuca. Pol. Tyg. Lek. 1993; 48 (25-26): 548-550.
52. Parker M.E.: Free PSA for detecting prostate cancer. JAMA 1998; 280 (21): 1825-1826.
53. Piomelli S.: A micromethod for free erythrocyte porphyrins: the FEP test. J. Lab. Clin. Med. 1973; 81: 932-940.
54. Lutz W., Krajewska B.: Markery nowotworowe i ich znaczenie w profilaktyce raka zawodowego. Pol. Tyg. Lek. 1990; 45 (32-33): 643-646.
55. Lutz W., Krajewska B.: Onkoproteiny i antyonkoproteiny surowicy krwi jako biomarkery wczesnych skutków zdrowotnych powodowanych przez kancerogeny zawodowe i środowiskowe. Med. Pr. 1996; 47 (5): 511-518.
56. Babich H., Alguacil M.N., Borenfreund E.: Arsenic-selenium interactions determined with cultured fish cells. Toxicol. Lett. 1989; 45: 157-164.
57. Hu G., Liu X., Liu J.: Protective effects of sodium selenite and selenomethionine on genotoxicity to human peripheral lymphocytes induced by arsenic. Chung. Hua. Yu. Fang. I. Hsueh. Tsa. Chih. 1996; 30 (1): 26-29.
58. Styblo M., Thomas D.J.: Selenium modifies the metabolism and toxicity of arsenic in primary rat hepatocytes. Toxicol. Appl. Pharmacol. 2001; 172 (1): 52-61.
59. Barret J.C., Oshimura M., Tsutsui T., Tanaka N.: Mutation and neoplastic transformation. Correlations and dissociations. An. N.Y. Acad. Sci. 1988; 534: 95-98.
60. Brown C.C., Chu K.C.: Implications of the multistage theory of carcinogenesis applied to occupational arsenic exposure. JNCI 1983; 70 (3): 455-463.